An additional consideration in regards to the lack of correlation between HSI and FGF-21 is that we did not try to differentiate between patients with viral steatosis due to the cytopathic effect of the virus, which are those that would exhibit the most significant reduction in steatosis in response to treatment, and those with metabolic steatosis due to a concomitant metabolic syndrome, which would only exhibit a modest decrease in fatty liver accumulation following viral eradication. The gene discussed is FGF21; the disease is metabolic syndrome.